Bloomberg
Alexandria Real Estate's Marcus on Interest Rates, Drug Pricing
Oct.29 -- Joel Marcus, chairman at Alexandria Real Estate Equities, discusses the risk of rising interest rates, how government action on drug pricing could impact the firm's pharmaceutical tenants, and exploring opportunities in the...
Bloomberg
J&J Has 'Tremendous, Deep Bench' of Leaders, CEO Says
Johnson & Johnson Chairman and CEO Alex Gorsky comments on J&J's recently announced executive changes as the health-care giant prepares for its CEO and top scientist to depart. He speaks during an interview with Bloomberg's David Westin...
Bloomberg
India's Pharma Stocks May Keep Rising: UTI International
Dec.23 -- Praveen Jagwani, chief executive officer of UTI International, India's largest asset manager, discusses the outlook for the economy and markets amid the coronavirs pandemic. India’s economic activity showed signs of stabilizing...
Bloomberg
Bringing High-Tech Healthcare to India’s Poor
Nov.20 -- How do you bring healthcare to rural India? Bloomberg’s Game Changers talks to a doctor-turned-entrepreneur who is bringing medical care to the poor. Video by Robin Fall.
Bloomberg
Cosgrove: We Will Not Have Price Controls on Drug Prices
Dec.08 -- Cleveland Clinic President and CEO Dr. Toby Cosgrove discusses drug prices and health care costs. He speaks with David Gura on “Bloomberg Markets.â€
Bloomberg
Vascepa Is Safe and Should Be Approved by End of Year, Amarin CEO Says
Aug.28 -- John Thero, Amarin Corp. chief executive officer, discusses the company's plans for its cardiovascular drug Vascepa. He speaks with Bloomberg's David Westin on "Balance of Power."